Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Christianne GroeneveldtJurriaan Q van GinkelPriscilla KindermanMarjolein SluijterLisa GriffioenCamilla LabrieDiana J M van den WollenbergWytske M van WeerdenSjoerd H Van der BurgPeter Ten DijkeLukas J A C HawinkelsThorbald van HallNadine van MontfoortPublished in: Cancer research communications (2023)
Blockade of the pleiotropic molecule TGF-β can both improve and impair the efficacy of viro-immunotherapy, depending on the tumor model. While TGF-β blockade antagonized Reo&CD3-bsAb combination therapy in the KPC3 model for pancreatic cancer, it resulted in 100% complete responses in the MC38 colon model. Understanding factors underlying this contrast is required to guide therapeutic application.